FTC Reports on Pharmaceutical Patent Settlement Agreements

The FTC issued its annual report on pharmaceutical patent settlement agreements that are required to be filed with the FTC under the 2003 Medicare Modernization Act. The chart below (taken from the FTC's report) categorizes the agreements based on whether there is a restriction on the generic's ability to compete and what compensation, if any, flows between the parties. As explained in the previous post, the Senate held hearings on reverse payment settlement agreements on Wednesday, and a bill may soon be introduced that outlaws such payments.